TITLE:
CCL4 Levels Differ between Aspirin-Tolerant and Aspirin-Intolerant Patients with Asthma
AUTHORS:
Juan Raymundo Velazquez, Gabriela Soid-Raggi, Luis Manuel Teran, Gandhi Fernando Romero-Pavon, Fernando Ramírez-Jimenez
KEYWORDS:
AERD, CCL4, Asthma
JOURNAL NAME:
Health,
Vol.9 No.11,
October
18,
2017
ABSTRACT: Aspirin-exacerbated respiratory disease (AERD) is an asthma phenotype characterized by nasal polyps, chronic hypertrophic eosinophilic sinusitis, asthma, and sensitivity to aspirin. Unawareness of this disease by patients and their physicians may have serious consequences because of the risk of near-fatal asthma. Its confirmative diagnosis can be established only by provocative aspirin challenge, which represents a potential risk for patient health. Purpose: Because CCL4 plays an important role in several pulmonary conditions, we tested its immunoreactivity in nasal lavages and sera from control subjects, and from aspirin-sensitive and non-aspirin-sensitive patients. Method: Immunoreactivity of CCL4 was measured in serum and nasal lavages from 30 healthy controls (HC), 23 patients with AERD, and 20 patients with aspirin-tolerant asthma (ATA). Additionally, a serum biobank contained sera from 90 HC, 83 patients with AERD, and 69 patients with ATA was employed. Results: The serum immunoreactivity of CCL4 could distinguish both types of asthma phenotypes. Conclusion: CCL4 may play an unexpected role in thephysiopathology of AERD.